Fig 1
The structure of scoparone and the effects of scoparone on U46619-induced platelet aggregation. (A) Chemical structure of scoparone. PIN: 6,7-Dimethoxy-2H-chromen-2-one, Chemical formula: C 1 1 H 1 0 O 4 , Molar mass: 206.19 g/moL. (B) Effects of scoparone pretreatment on U46619-stimulated platelet aggregation. (C) Cytotoxicity of scoparone on human platelets. Washed platelets (10
![Fig. 3 Effects of scoparone on IP 3 R phosphorylation and [Ca 2 + ] i...](publication/338278954/figure/fig3/AS:842224816365569@1577813452605/Effects-of-scoparone-on-IP-3-R-phosphorylation-and-Ca-2-i-mobilization-A-Effects_Q320.jpg)
Contexts in source publication
Context 1
... Scoparone (6,7-Dimethoxy-2H-chromen-2-one) was purchased from Avention Corporation (Seoul, Korea) (Fig. 1). Chrono-Log Corporation (Havertown, PA, USA) provided U46619. Both cAMP and cGMP enzyme immunoassay (EIA) kits were received from Cayman Chemical (Ann Arbor, MI, USA). Fura 2-AM and Fibrinogen Alexa Fluor 488 conjugates were purchased from Invitrogen (Eugene, OR, USA). Anti-VASP, anti-phosphor-VASP Ser 239 , anti-phosphor-VASP Ser 157 ...
Context 2
... of scoparone on U46619-induced human platelet aggregation U46619 at 0.5 μM induces the optimum aggregation of human platelets, and in this study, U46619-induced platelets aggregation rate was 80.5% (Fig. 1B). However, platelets treated with scoparone (5,10,30, and 50 μM) had aggregation rates that were significantly reduced (6.5, 40.4, 85.1, and 93.8%, respectively) without cytotoxicity (Fig. 1C), which indicates that scoparone inhibited U46619-induced platelet aggregation in a dose-dependent ...
Context 3
... aggregation U46619 at 0.5 μM induces the optimum aggregation of human platelets, and in this study, U46619-induced platelets aggregation rate was 80.5% (Fig. 1B). However, platelets treated with scoparone (5,10,30, and 50 μM) had aggregation rates that were significantly reduced (6.5, 40.4, 85.1, and 93.8%, respectively) without cytotoxicity (Fig. 1C), which indicates that scoparone inhibited U46619-induced platelet aggregation in a dose-dependent ...
Context 4
... the other hand, cyclic nucleotides is known to inhibit platelet aggregation by reducing [Ca 2+ ] i and activating cAMP-and cGMP-dependent protein kinase (PKA and PKG) [18]. In this study, scoparone significantly inhibited U46619-induced platelets aggregation without cytotoxicity (Fig. 1). In addition, scoparone increased cAMP and cGMP production in platelets in a concentrationdependent manner, and suppressed [Ca 2+ ] i concentrations. These results indicate that increased scoparone-induced cyclic nucleotides played a central role in inhibiting platelet activity by downregulating [Ca 2+ ] i . Increased cAMP and cGMP can ...
Similar publications
Production and process controls, organization and personnel, were the top problems found, while packaging and labelling citations increased in 2017 and 2018.
Citations
... It has been reported that scoparone inhibits IL-1βmediated inflammatory responses by modulating the PI3K/Akt/ NF-κB pathway and thus may be a therapeutic material for joint diseases [18][19][20]. A previous study has shown that scoparone has the effect of inhibiting thrombus formation through the regulation of cyclic nucleotides in U46619-induced platelets [21]. However, the role of scoparone in platelet aggregation and the mechanism of scoparone on human platelets induced by collagen are currently unknown. ...
